Aggregated News
The development of genomics for public health is being prioritised mainly by low- and middle-income nations, with richer countries not seeking to collaborate in such research, reports the Organisation for Economic Cooperation and Development (OECD).
Yet while there are to date relatively few examples of genomics being applied successfully for developing stratified medicines, the use of genomics more broadly for infectious disease control is already yielding significant public health benefits, in terms of helping to diagnose and track the movement of disease outbreaks and also to enhance and accelerate the production of effective vaccines, says the OECD.
The Organisation was reporting on its investigation, with the UK-based ESRC Genomics Network into the drivers and criteria shaping the application of genomic biotechnology to health in different national settings, and the barriers to implementation, both national and international.
They found "significant differences of priority" between higher-income countries - which are motivated primarily by the promise of stratified medicine as a means of addressing their growing burden of chronic disease - and lower- and middle-income countries, which tend to concentrate more on efforts...
Yet while there are to date relatively few examples of genomics being applied successfully for developing stratified medicines, the use of genomics more broadly for infectious disease control is already yielding significant public health benefits, in terms of helping to diagnose and track the movement of disease outbreaks and also to enhance and accelerate the production of effective vaccines, says the OECD.
The Organisation was reporting on its investigation, with the UK-based ESRC Genomics Network into the drivers and criteria shaping the application of genomic biotechnology to health in different national settings, and the barriers to implementation, both national and international.
They found "significant differences of priority" between higher-income countries - which are motivated primarily by the promise of stratified medicine as a means of addressing their growing burden of chronic disease - and lower- and middle-income countries, which tend to concentrate more on efforts...